Rare Diseases

Dedicated to orphan drug development

Orphan Drug Development

SXR Laboratories specializes in rare disease trials, working with patient advocacy groups and regulatory authorities to develop treatments for underserved populations with life-threatening conditions.

Expertise

Genetic disorder studies
Metabolic disease trials
Orphan drug designation support
Natural history studies
Patient registry development
Adaptive trial designs

Foundational Technologies & Key Targets

Molecular Targets

AAV Vector Delivery: Using adeno-associated virus to deliver functional genes for monogenic disorders. This is the primary therapeutic approach for many rare diseases.

CRISPR-Cas9: Precision gene editing to correct disease-causing mutations at their source, including therapies for Beta-thalassemia and Sickle Cell Disease.

ASOs (Antisense Oligonucleotides): Gene silencing for conditions like Spinal Muscular Atrophy (SMA), where silencing or modifying gene expression can restore protein function.

Key Disease Targets

CFTR: Cystic Fibrosis Transmembrane Conductance Regulator, defective in Cystic Fibrosis. SMN1: Survival Motor Neuron 1 gene, deficient in Spinal Muscular Atrophy. Lysosomal Enzymes: Various enzyme deficiencies causing lysosomal storage diseases (Gaucher, Fabry, Pompe diseases).

Therapeutic Modalities

Gene Therapy: Direct correction of genetic defects (e.g., AAV-CFTR for Cystic Fibrosis). Enzyme Replacement Therapy (ERT): Providing missing enzymes for lysosomal storage diseases. Gene Editing: CRISPR-based approaches for permanent correction of blood disorders like Beta-thalassemia. Ex Vivo Gene Therapy: Modifying patient cells outside the body (particularly for blood disorders) and reinfusing them.

Patient-Centric Approach

We collaborate closely with patient communities, employing innovative trial designs and outcome measures appropriate for small populations while maintaining scientific rigor.

Integrated Research Excellence

Rare disease research demands exceptional collaboration across specialized services. Clinical Trials Management implements patient-centric protocols with flexible enrollment and home-based visits to accommodate small, geographically dispersed populations. Regulatory Affairs secures orphan drug designations and navigates expedited pathways essential for bringing treatments to underserved patients. Biostatistics applies innovative designs suited for small sample sizes, including N-of-1 and basket trials. Data Management creates comprehensive patient registries and natural history databases. Medical Writing crafts compelling orphan drug applications, while Quality Assurance maintains rigorous standards despite trial complexities.